Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHaleon Regulatory News (HLN)

Share Price Information for Haleon (HLN)

Share Price is delayed by 15 minutes
Get Live Data
326.60    5.40 (1.68%)
Bid:
326.50
Ask:
326.70
Spread: 0.20 (0.061%)
Market Cap: £28.90b
HLN Live PriceLast checked at - London Stock Exchange

Intraday Haleon Share Chart

Board Changes

5 Dec 2024 10:00

RNS Number : 9658O
Haleon PLC
05 December 2024
 

 

 

Haleon plc: Board Changes

 

5 December 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces the following changes to the Board.

 

Following the reduction of Pfizer Inc.'s shareholding in Haleon plc below 20%, and in line with the Pfizer Relationship Agreement with Haleon plc, David Denton, Non-Executive Director and

representative of Pfizer Inc., stepped down from the Board on 4 December 2024.

 

Bláthnaid Bergin has been appointed as an independent Non-Executive Director and will join the Haleon Board on 24 February 2025.

 

Bláthnaid Bergin brings financial leadership and strategic planning experience from a variety of consumer-facing businesses. Bláthnaid is currently the Chief Financial Officer of J Sainsbury plc, where she has played a pivotal role in driving the company's financial strategy and operational efficiency initiatives. Prior to joining Sainsbury's, Bláthnaid held senior finance leadership and international positions at Aviva, RSA and GE working across Europe, Asia and Australia. She is a Chartered Accountant. Bláthnaid was previously Non-Executive Director, Chair of the Audit Committee and Senior Independent Director for Artemis Alpha Investment Trust.

 

Sir Dave Lewis, Haleon's Chair commented: "On behalf of the Board, I would like to thank Dave for his insights and contributions to the Board's discussions. We wish him all the very best for the future. I would like to welcome Bláthnaid to Haleon. With her strong track record of financial leadership and transformation from multiple consumer-facing businesses, Bláthnaid brings a wealth of relevant skills and experience to the Board."

 

The Company confirms that there is no further information to be disclosed under the requirements of UKLR 6.4.6R and 6.4.8R.

 

Amanda Mellor 

Company Secretary 

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFSLSUIELSEDE
Date   Source Headline
1st Jun 20269:45 amRNSTotal Voting Rights and Capital
1st Jun 20267:00 amRNSTransactions in Own Shares
26th May 20267:00 amRNSTransactions in Own Shares
22nd May 202612:30 pmRNSDirector/PDMR Shareholding
18th May 20262:30 pmRNSDirector/PDMR Shareholding
18th May 20267:00 amRNSTransactions in Own Shares
11th May 20267:00 amRNSTransactions in Own Shares
7th May 20264:26 pmRNSEMTN programme publication of listing particulars
5th May 20267:00 amRNSTransactions in Own Shares
1st May 20263:30 pmRNSTotal Voting Rights and Capital
29th Apr 20264:48 pmRNSResults of Haleon 2026 Annual General Meeting
29th Apr 20267:00 amRNSHaleon 2026 Q1 Trading Statement
27th Apr 20267:00 amRNSTransactions in Own Shares
20th Apr 20267:00 amRNSTransactions in Own Shares
13th Apr 20267:00 amRNSTransactions in Own Shares
7th Apr 20267:00 amRNSTransactions in Own Shares
1st Apr 20269:00 amRNSTotal Voting Rights and Capital
30th Mar 20267:00 amRNSTransactions in Own Shares
24th Mar 20263:00 pmRNSDirector/PDMR Shareholding
23rd Mar 20267:00 amRNSTransactions in Own Shares
16th Mar 20267:00 amRNSTransactions in Own Shares
16th Mar 20267:00 amRNSTransactions in Own Shares
13th Mar 20262:30 pmRNSDirector/PDMR Shareholding
13th Mar 20262:00 pmRNSPublication of Annual Report 2025 & Notice of AGM
12th Mar 202610:00 amRNSCommencement of £500m Share Buyback Programme
2nd Mar 20269:30 amRNSTotal Voting Rights and Capital
25th Feb 20267:00 amRNSHaleon Preliminary 2025 Full Year Results
12th Feb 20269:00 amRNSDirector/PDMR Shareholding
2nd Feb 20263:30 pmRNSTotal Voting Rights and Capital
21st Jan 20262:45 pmRNSDirector Declaration
8th Jan 20261:30 pmRNSEvolution of operating model
6th Jan 20262:00 pmRNSDirector/PDMR Shareholding
2nd Jan 20267:00 amRNSTotal Voting Rights and Capital
2nd Jan 20267:00 amRNSTotal Voting Rights and Capital
15th Dec 202510:00 amRNSBoard and Committee Changes
10th Dec 20253:15 pmRNSDirector/PDMR Shareholding
1st Dec 202510:30 amRNSTotal Voting Rights and Capital
12th Nov 202511:00 amRNSDirector/PDMR Shareholding
10th Nov 20257:00 amRNSAppointment of Vindi Banga as Chair
3rd Nov 202511:30 amRNSTotal Voting Rights and Capital
30th Oct 20257:00 amRNSHaleon 2025 Q3 Trading Statement
10th Oct 202512:45 pmRNSDirector/PDMR Shareholding
2nd Oct 202510:05 amRNSDirector Declaration
2nd Oct 20257:00 amRNSTransaction in Own Shares & Buyback Update
1st Oct 202510:00 amRNSTotal Voting Rights and Capital
1st Oct 20257:00 amRNSTransaction in Own Shares
30th Sep 20257:00 amRNSTransaction in Own Shares
29th Sep 20257:00 amRNSTransaction in Own Shares
26th Sep 20251:30 pmRNSDirector/PDMR Shareholding
26th Sep 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.